Journal Watch · Nature Communications · 2026

IRAK2 deficiency causes immune dysregulation through defective Myddosome assembly and enhanced interferon responses.

Here, we show IRAK2 deficiency as a monogenic immune dysregulation disorder.

Fei Y, Liu L, Ma S et al.Nature Communications3 min readPharma relevance 65/100

DOI: 10.1038/s41467-026-73383-8PMID: 42168171Study type: preclinical (animal / model) study

TL;DR

Here, we show IRAK2 deficiency as a monogenic immune dysregulation disorder.

Key findings

  • Mechanistically, our data are consistent with engagement of a TRIF-dependent interferon pathway.
  • Baricitinib attenuates the elevated interferon signature in patient-derived cells ex vivo and cell lines.
  • Here, we show IRAK2 deficiency as a monogenic immune dysregulation disorder.

What they did

Two patients were clinically diagnosed with primary immunodeficiency, while the majority fulfill diagnostic criteria for autoimmune or autoinflammatory diseases. The IRAK2-∆ex2 protein fails to interact with IRAK4, leading to impaired activation of nuclear factor kappa B signaling via the Myddosome complex. An elevated type I interferon signature is observed in the patients, which is confirmed in bone marrow-derived macrophages from knock-in mice and knockout cell lines.

Full abstract (original)

Background: Interleukin-1 receptor-associated kinase 2 (IRAK2) is essential for the Myddosome complex formation downstream of Toll-like receptors. We identify twelve patients with a homozygous loss-of-function copy number variant in IRAK2, designated IRAK2-∆ex2. Most patients present with recurrent infections, autoantibody production, and gastrointestinal ulceration.

What they did: Two patients were clinically diagnosed with primary immunodeficiency, while the majority fulfill diagnostic criteria for autoimmune or autoinflammatory diseases. The IRAK2-∆ex2 protein fails to interact with IRAK4, leading to impaired activation of nuclear factor kappa B signaling via the Myddosome complex. An elevated type I interferon signature is observed in the patients, which is confirmed in bone marrow-derived macrophages from knock-in mice and knockout cell lines.

Results & conclusions: Mechanistically, our data are consistent with engagement of a TRIF-dependent interferon pathway. Baricitinib attenuates the elevated interferon signature in patient-derived cells ex vivo and cell lines. Here, we show IRAK2 deficiency as a monogenic immune dysregulation disorder.

Abstract © the authors / Nature Communications (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1038/s41467-026-73383-8 · PubMed 42168171.

Why it matters for pharma & biotech

  • Relevant to General & Medicine teams tracking Nature Communications for new targets, mechanisms and biomarkers.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Nature Communications study find?

Here, we show IRAK2 deficiency as a monogenic immune dysregulation disorder.

What type of study is this?

It is a preclinical (animal / model) study, published in Nature Communications in 2026. Two patients were clinically diagnosed with primary immunodeficiency, while the majority fulfill diagnostic criteria for autoimmune or autoinflammatory diseases.

Where can I read the original paper?

The original is at the publisher via DOI 10.1038/s41467-026-73383-8. PubMed ID: 42168171. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Fei Y, Liu L, Ma S et al.. IRAK2 deficiency causes immune dysregulation through defective Myddosome assembly and enhanced interferon responses.. Nature Communications (2026). DOI: 10.1038/s41467-026-73383-8.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/irak2-deficiency-causes-immune-dysregulation-through-defective-myddosome-733838/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides